Endocan, VEGF and TNF-alpha Levels in Periodontal Disease and After Treatment

Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A and Tumor Necrosis Factor Alpha Levels

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02750956

Enrollment

Registered

2016-04-26

Start date

2015-06-30

Completion date

2016-03-31

Last updated

2016-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Disease

Keywords

endocan protein, VEGF A, TNF-alpha, after treatment

Brief summary

The primer aim of the study was to determine serum and gingival crevicular fluid (GCF) endocan levels in periodontal diseases pathogenesis supported with vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) levels.

Detailed description

The study consist of three groups: periodontally healthy individuals (group 1; n = 20), individuals with generalized chronic periodontitis (group 2; n = 20), the same patients with chronic periodontitis after they had been treated with scaling and root planing (SRP) were considered as Group 3. Clinical measurements were recorded; GCF and serum samples were obtained from each participant before and 6 weeks after therapy. Endocan, VEGF-A and TNF-α levels were measured by enzyme-linked immunosorbent assay.

Interventions

PROCEDURENon-surgical periodontal treatment

Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

Group 1 Inclusion Criteria: * No bone and attachment loss, * GI=0, PPD≤3mm, CAL≤3mm * Systematically healthy patients Group 2 Inclusion Criteria: * GI\>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically. * Systematically healthy patients

Exclusion criteria

* Aggressive Periodontitis, * Oral pathologies, * Patients with any other systemic diseases, * Pregnant women and those in the lactation period, * Patients with smoking habit and taking medication * Patients received periodontal therapy in last 6 months

Design outcomes

Primary

Measure	Time frame	Description
Endocan levels	6 weeks	Change after periodontal treatment

Secondary

Measure	Time frame	Description
VEGF levels	6 weeks	Change after periodontal treatment
TNF-alpha levels	6 weeks	Change after periodontal treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026